Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
出版年份 2020 全文链接
标题
Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
作者
关键词
-
出版物
CNS Neuroscience & Therapeutics
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-04-24
DOI
10.1111/cns.13380
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma
- (2019) Shasha Liu et al. OncoImmunology
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas
- (2019) Jun Su et al. Frontiers in Genetics
- The TCGA Legacy
- (2018) CELL
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
- (2018) Elisa Peranzoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Immune microenvironment of gliomas
- (2017) Anna Gieryng et al. LABORATORY INVESTIGATION
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Immune Checkpoint in Glioblastoma: Promising and Challenging
- (2017) Jing Huang et al. Frontiers in Pharmacology
- Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples
- (2017) Guanzhang Li et al. OncoImmunology
- Tumor infiltrating immune cells in gliomas and meningiomas
- (2016) Patrícia Domingues et al. BRAIN BEHAVIOR AND IMMUNITY
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Erratum: Corrigendum: Structural and functional features of central nervous system lymphatic vessels
- (2016) Antoine Louveau et al. NATURE
- PD-1 says goodbye, TIM-3 says hello
- (2016) Diana Romero Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation
- (2016) Hiroshi Iwata et al. Nature Communications
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Targeting immune checkpoints in malignant glioma
- (2016) Xuhao Zhang et al. Oncotarget
- Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma
- (2016) Zheng Wang et al. OncoImmunology
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- The epidemiology of glioma in adults: a "state of the science" review
- (2015) L. L. Morgan NEURO-ONCOLOGY
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models
- (2014) Y. Zhu et al. CANCER RESEARCH
- DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells
- (2014) Samia B Bachmann et al. Molecular Cancer
- Glioblastoma and Other Malignant Gliomas
- (2013) Antonio Omuro JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN -STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma
- (2013) R. Camicia et al. JOURNAL OF CELL SCIENCE
- Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types
- (2013) A. M. Griesinger et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started